Latiotim (Latanoprost, Timolol)

Latanoprost, a prostaglandin analog, increases uveoscleral outflow of aqueous humor, while timolol, a non‑selective beta‑adrenergic blocker, decreases aqueous humor production. The combined effect lowers intra‑ocular pressure more effectively than either component alone.

The dosing regimen for Latiotim is determined by the prescribing clinician. Typically, one drop is instilled in the affected eye(s) once daily in the evening, but the exact schedule and number of drops are individualized based on patient response and tolerability.

Safety data for Latiotim during pregnancy and lactation are limited. The product should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with monotherapy agents, the latanoprost/timolol combination offers dual mechanisms—enhanced outflow and reduced production—resulting in greater intra‑ocular pressure reduction. It may be preferred when a single‑agent regimen does not achieve target pressure, though individual response and tolerance vary.

Latiotim eye drops should be stored at room temperature, below 25 °C, in the original container. Protect the bottle from light and moisture, and keep it out of reach of children. Do not freeze the product.

The eye drops are applied topically. After washing hands, tilt the head back, pull down the lower eyelid to form a pocket, and instill one drop into the conjunctival sac of each prescribed eye. Close the eye gently for a few seconds and avoid blinking excessively.

Serious adverse events, although rare, include severe allergic reactions, persistent eye pain, sudden loss of vision, and systemic beta‑blocker effects such as bradycardia, hypotension or bronchospasm. Patients should seek immediate medical attention if any of these occur.

Latiotim is contraindicated in patients with known hypersensitivity to latanoprost, timolol or any component of the formulation, and in individuals with asthma, chronic obstructive pulmonary disease, severe bradycardia, or sinus node dysfunction due to the beta‑blocker component. Consultation with a healthcare professional is required before use.